DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

Phase 2

Active, not recruiting

Conditions: Epitheliod Malignant Pleural Mesothelioma

Interventions: Radiation: Photodynamic Therapy
Radiation: Chemotherapy
Procedure: Radical Pleurectomy
Drug: Photofrin 2.0 mg/kg

First Posted Date: 2014-06-03

Last Posted Date: 2024-12-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 52

Registration Number: NCT02153229

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Patient-Centered Acupuncture for Pain (PCAP)

Completed

Conditions: Cancer Survivors

Interventions: Behavioral: Survey

First Posted Date: 2014-06-02

Last Posted Date: 2015-01-14

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 36

Registration Number: NCT02152020

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer

Completed

Conditions: Prostate Cancer

Interventions: Radiation: Radiotherapy
Other: Eischens Yoga

First Posted Date: 2014-05-12

Last Posted Date: 2021-05-19

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 68

Registration Number: NCT02135653

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Radiation: Radiotherapy

First Posted Date: 2014-05-12

Last Posted Date: 2024-11-20

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 204

Registration Number: NCT02135679

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy

Not Applicable

Completed

Conditions: Gynecological Malignancy Requiring Definitive Radiotherapy
Gastrointestinal Cancer
Colorectal Cancer
Head and Neck Cancer
Rectal Cancers
Biopsy Proven Non Small Cell Lung Cancer

Interventions: Diagnostic Test: CT scan

First Posted Date: 2014-05-05

Last Posted Date: 2022-07-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 74

Registration Number: NCT02130427

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

Completed

Conditions: Gynecologic Cancer

Interventions: Radiation: [18F]Fluorothymidine (FLT) PET/CT Imaging

First Posted Date: 2014-04-09

Last Posted Date: 2021-03-30

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 15

Registration Number: NCT02108457

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Acupuncture Feasibility Trial for Dyspnea in Lung Cancer

Phase 1

Completed

Conditions: Dyspnea
Lung Cancer

Interventions: Procedure: Acupuncture

First Posted Date: 2014-03-24

Last Posted Date: 2019-07-23

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 12

Registration Number: NCT02094950

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

DC Vaccine for Patients With Ductal Carcinoma In Situ

Phase 1

Completed

Conditions: DCIS
Breast Cancer

Interventions: Biological: HER-2 Pulsed Dendritic cell Vaccine

First Posted Date: 2014-02-12

Last Posted Date: 2020-04-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 58

Registration Number: NCT02061332

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Pancreas

Interventions: Drug: Paricalcitol
Drug: Gemcitabine
Drug: Abraxane

First Posted Date: 2014-01-09

Last Posted Date: 2024-02-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 15

Registration Number: NCT02030860

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Drug: HCQ

First Posted Date: 2013-12-17

Last Posted Date: 2020-04-20

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 8

Registration Number: NCT02013778

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy